CMTM3通过NF-κB信号通路调控胶质母细胞瘤U251细胞的增殖与迁移
研究利用TCGA和GTEx数据库分析及11例胶质母细胞瘤(GBM)患者组织样本,发现CMTM3在GBM中高表达且高表达者总生存率和无病生存率较低。体外实验表明CMTM3通过NF-κB信号通路调控U251细胞增殖和迁移,裸鼠成瘤实验显示CMTM3影响体内肿瘤生长。
要点
- CMTM3在GBM组织及细胞系中高表达,高表达患者总生存率和无病生存率较低。
- 沉默CMTM3抑制U251细胞增殖和迁移,过表达则增强,该效应可被NF-κB抑制剂PDTC逆转。
- 裸鼠皮下成瘤实验中沉默CMTM3减小肿瘤体积,过表达增大肿瘤体积。
核心结论
- 在GBM中CMTM3呈高表达,且CMTM3高表达患者的总生存率和无病生存率降低。
- CMTM3通过NF-κB信号通路调控U251细胞的增殖和迁移能力。
研究设计与样本
- 利用TCGA和GTEx数据库分析CMTM3在GBM中的差异表达及对预后的影响。
- 对2022年11月3日至2023年3月15日贵州医科大学附属医院手术治疗的11例GBM患者的GBM组织和癌旁组织进行免疫组化染色和蛋白含量测定。
- 在GBM细胞系U87、U251、LN229和人胶质细胞系NHA中采用RT-qPCR和Western blot验证CMTM3表达。
- 利用U251细胞构建沉默和过表达CMTM3的稳转细胞株(sh-CMTM3组和OE-CMTM3组),进行CCK-8、流式细胞术、Transwell实验、NF-κB激活-核转运实验及裸鼠皮下成瘤实验。
主要发现
- 生物信息学分析显示CMTM3在GBM组织中高表达,CMTM3高表达组患者总生存率和无病生存率均低于低表达组(P值分别为0.010和0.032)。
- 11例GBM组织样本中10例癌组织CMTM3蛋白表达量高于相应癌旁组织,这10例癌组织总体为0.44±0.09,高于癌旁组织的0.12±0.02(t=6.69,P<0.001);1例癌组织为0.15±0.01,癌旁组织为0.17±0.08,差异无统计学意义(t=0.32,P=0.750)。
- RT-qPCR显示NHA细胞CMTM3 mRNA表达量为1.0±0.1,U87、LN229和U251细胞分别为2.1±0.3、3.4±0.5和3.7±0.8,均高于NHA细胞(均P<0.01);Western blot显示U87、LN229和U251细胞CMTM3蛋白表达量分别为1.5±0.2、1.8±0.2和1.9±0.1,均高于NHA细胞的0.7±0.2(均P<0.01),U251细胞中表达水平最高。
- sh-CMTM3组细胞活性被抑制,G0/G1期细胞比例增多(P<0.01),S期细胞比例减少(P<0.01),细胞迁移数为(233.6±35.5)个,低于sh-NC组(P<0.001);OE-CMTM3组细胞活性增强,G0/G1期细胞比例减少(P<0.01),S期细胞比例增多(P<0.01),细胞迁移数为(1212.0±20.8)个,高于OE-NC组(P<0.001);OE-CMTM3+PDTC组细胞活性、G1期、S期和G2期细胞比例、细胞迁移数均无明显变化(均P>0.05)。
- sh-CMTM3组p-p65/p65比值为0.51±0.04,p-IκBα/IκBα比值为0.39±0.03,均低于sh-NC组(均P<0.01),细胞质染色率为(49.29±1.98)%,高于sh-NC组(P<0.01);OE-CMTM3组p-p65/p65比值为2.27±0.10,p-IκBα/IκBα为2.14±0.15,均高于OE-NC组(均P<0.01),细胞质染色率为(18.96±1.44)%,低于OE-NC组(P<0.01);OE-CMTM3+PDTC组p65/p65比值、p-IκBα/IκBα比值和细胞质染色率与OE-NC组差异均无统计学意义(均P>0.05)。
关键数值与推荐
- CMTM3高表达组GBM患者总生存率低于低表达组(P=0.010),无病生存率亦低于低表达组(P=0.032)。
- 10例GBM癌组织CMTM3蛋白表达量总体为0.44±0.09,高于癌旁组织的0.12±0.02(P<0.001)。
- sh-CMTM3组细胞迁移数为(233.6±35.5)个,低于sh-NC组(P<0.001);OE-CMTM3组细胞迁移数为(1212.0±20.8)个,高于OE-NC组(P<0.001)。
- sh-CMTM3组裸鼠肿瘤体积为(408.9±96.2)mm³,小于sh-NC组(P=0.003);OE-CMTM3组为(1514.5±251.5)mm³,大于OE-NC组(P=0.005)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the effects and potential mechanisms of chemokine-like factor-like MARVEL transmembrane domain-containing Protein 3 (CMTM3) on the proliferation and migration of glioblastoma (GBM) cells. Methods: Using CMTM3 expression data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases, we analyzed the differential expression of CMTM3 in GBM tissues and its impact on the prognosis of GBM patients. Immunohistochemical staining and protein content determination of CMTM3 was performed on GBM and adjacent non-cancerous tissue samples from 11 GBM patients who underwent surgical treatment at the Affiliated Hospital of Guizhou Medical University between November 3, 2022 and March 15, 2023. Additionally, the expression of CMTM3 was validated in GBM cell lines U87, U251, LN229, and the human astrocyte (NHA) cell line using real-time quantitative polymerase chain reaction (RT-qPCR) and Western blot analyses. Stable cell lines with silenced and overexpressed CMTM3 (sh-CMTM3 group and OE-CMTM3 group) were constructed using U251 cells. The effect of CMTM3 expression on cell proliferation was assessed using the Cell Counting Kit-8 (CCK-8) assay. Flow cytometry was employed to examine the impact of CMTM3 expression on the cell cycle. Transwell assays were conducted to evaluate the influence of CMTM3 expression on cell migration. Bioinformatics analysis, Western blotting, NF-κB activation-nuclear translocation assays, and the NF-κB pathway inhibitor pyrrolidine dithiocarbamate ammonium (PDTC) were used to validate the effect of CMTM3 on the NF-κB pathway. Finally, a subcutaneous tumorigenesis assay in nude mice was performed to observe the impact of CMTM3 expression on the in vivo growth of U251 cells. Results: Bioinformatics analysis revealed that CMTM3 is highly expressed in GBM tissues. Patients with a high CMTM3 expression had lower overall survival (OS) and disease-free survival (DFS) rates compared with those with a low CMTM3 expression (with P values of 0.010 and 0.032, respectively). Among the 11 GBM pathological specimens, 10 samples exhibited higher CMTM3 protein expression levels in the cancerous tissue compared with the adjacent non-cancerous tissue. The average CMTM3 protein expression in these samples was 0.44±0.09, significantly higher than that in the adjacent non-cancerous tissues (0.12±0.02, P<0.001). In one sample, the difference in CMTM3 protein expression between the cancerous and adjacent non-cancerous tissues was not statistically significant (P=0.750).The RT-qPCR results showed that the mRNA expression level of CMTM3 in NHA cells was 1.0±0.1, whereas in GBM cells U87, LN229, and U251, the levels were 2.1±0.3, 3.4±0.5, and 3.7±0.8, respectively, all significantly higher than that in NHA cells (all P<0.01). Western blot results demonstrated that the protein expression levels of CMTM3 in GBM cells U87, LN229, and U251 were 1.5±0.2, 1.8±0.2, and 1.9±0.1, respectively, also higher than that in NHA cells (0.7±0.2, all P<0.01), with the highest level observed in U251 cells. The CCK-8 assay, Flow cytometry, and Transwell migration experiments indicated that cell viability was inhibited in the sh-CMTM3 group, with an increase in the proportion of cells in the G0/G1 phase (P<0.01) and a decrease in the S phase (P<0.01), and the number of migrated cells was 233.6±35.5, lower than that in the sh-NC group (P<0.001). Conversely, the OE-CMTM3 group showed enhanced cell viability, a reduction in the proportion of cells in the G0/G1 phase (P<0.01), and an increase in the S phase (P<0.01), and the number of migrated cells was 1212.0±20.8, higher than that in the OE-NC group (P<0.001). However, in the OE-CMTM3+PDTC group, cell viability, cell cycle distribution (G1, S, and G2 phases), and cell migration numbers showed no significant changes (all P>0.05). Western blot analysis and NF-κB activation-nuclear translocation assay results indicated that in the sh-CMTM3 group, the p-p65/p65 ratio was 0.51±0.04 and the p-IκBα/IκBα ratio was 0.39±0.03, both lower than those in the sh-NC group (both P<0.01). The cytoplasmic staining rate was (49.29±1.98)%, higher than that in the sh-NC group (P<0.01). In the OE-CMTM3 group, the p-p65/p65 ratio was 2.27±0.10 and the p-IκBα/IκBα ratio was 2.14±0.15, both higher than those in the OE-NC group (both P<0.01). The cytoplasmic staining rate was (18.96±1.44)%, lower than that in the OE-NC group (P<0.01). In the OE-CMTM3+PDTC group, there were no significant differences in the p-p65/p65 ratio, p-IκBα/IκBα ratio, and cytoplasmic staining rate compared with the OE-NC group (all P>0.05). The subcutaneous tumorigenesis assay in nude mice showed that the tumor volume in the sh-CMTM3 group was (408.9±96.2) mm³, smaller than that in the sh-NC group (P=0.003). The tumor volume in the OE-CMTM3 group was (1 514.5±251.5) mm³, larger than that in the OE-NC group (P=0.005). Conclusions: In GBM, CMTM3 is highly expressed and negatively correlated with both OS and DFS of patients. CMTM3 regulates the proliferation and migration abilities of U251 cells through the NF-κB signaling pathway. 目的: 探讨趋化素样因子样含MARVEL跨膜结构域3(CMTM3)对胶质母细胞瘤(GBM)细胞增殖和迁移的影响及可能机制。 方法: 利用癌症基因组图谱(TCGA)和基因型-组织表达(GTEx)数据库中的CMTM3表达数据,分析CMTM3在GBM组织中的差异表达及其对GBM患者预后的影响。通过对取自2022年11月3日至2023年3月15日贵州医科大学附属医院手术治疗的11例GBM患者的GBM组织和癌旁组织样本进行CMTM3的免疫组化染色和蛋白含量测定、对GBM细胞系U87、U251、LN229和人胶质细胞系NHA进行CMTM3的实时荧光定量聚合酶链反应(RT-qPCR)、Western blot检测加以验证。利用U251细胞构建沉默和过表达CMTM3的稳转细胞株(sh-CMTM3组和OE-CMTM3组),采用细胞计数试剂盒8(CCK-8)实验检测CMTM3表达对细胞增殖能力的影响,采用流式细胞术检测CMTM3表达对细胞周期的影响,采用Transwell实验检测CMTM3表达对细胞迁移能力的影响,采用生信分析方法、Western blot检测、核因子κB(NF-κB)激活-核转运实验以及NF-κB通路抑制剂吡咯烷二硫代甲酸铵(PDTC)来验证CMTM3对NF-κB通路的影响。最后通过裸鼠皮下成瘤实验观察CMTM3表达对U251细胞在体内生长的影响。 结果: 生物信息学分析显示,CMTM3在GBM组织中高表达,CMTM3高表达组GBM患者的总生存率和无病生存率均低于CMTM3低表达组(P值分别为0.010和0.032)。11例GBM组织样本中,有10例CMTM3蛋白的表达量分别高于相应患者的癌旁组织,这10例GBM组织样本中CMTM3蛋白的表达量总体为0.44±0.09,高于癌旁组织中CMTM3蛋白的表达量(0.12±0.02;t=6.69,P<0.001)。只有1例GBM组织组织中CMTM3蛋白的表达量为0.15±0.01,其相应癌旁组织中CMTM3蛋白的表达量为0.17±0.08,差异无统计学意义(t=0.32,P=0.750)。RT-qPCR检测结果显示,人胶质细胞NHA中CMTM3 mRNA的表达量为1.0±0.1,GBM细胞U87、LN229和U251中CMTM3 mRNA的表达量分别为2.1±0.3、3.4±0.5和3.7±0.8,均高于NHA细胞(1.0±0.1,均P<0.01)。Western blot检测结果显示,GBM细胞U87、LN229和U251中CMTM3蛋白的表达量分别为1.5±0.2、1.8±0.2和1.9±0.1,均高于NHA细胞(0.7±0.2,均P<0.01),其中U251细胞中表达水平最高。CCK-8法、流式细胞术、Transwell细胞迁移实验检测结果显示,sh-CMTM3组细胞活性被抑制,G0/G1期细胞比例增多(P<0.01),S期细胞比例减少(P<0.01),细胞迁移数为(233.6±35.5)个,低于sh-NC组(P<0.001);OE-CMTM3组细胞活性增强,G0/G1期细胞比例减少(P<0.01),S期细胞比例增多(P<0.01),细胞迁移数为(1 212.0±20.8)个,高于OE-NC组(P<0.001);OE-CMTM3+PDTC组细胞活性,G1期、S期和G2期细胞比例,细胞迁移数均无明显变化(均P>0.05)。Western blot检测和NF-κB激活-核转运实验结果显示,sh-CMTM3组细胞中p-p65/p65比值为0.51±0.04,p-IκBα/IκBα比值为0.39±0.03,均低于sh-NC组(均P<0.01),细胞质染色率为(49.29±1.98)%,高于sh-NC组(P<0.01)。OE-CMTM3组细胞中p-p65/p65比值为2.27±0.10,p-IκBα/IκBα为2.14±0.15,均高于OE-NC组(均P<0.01),细胞质染色率为(18.96±1.44)%,低于OE-NC组(P<0.01),OE-CMTM3+PDTC组细胞中p65/p65比值、p-IκBα/IκBα比值和细胞质染色率与OE-NC组差异均无统计学意义(均P>0.05)。裸鼠皮下成瘤实验显示,sh-CMTM3组肿瘤体积为(408.9±96.2)mm3,小于sh-NC组(P=0.003),OE-CMTM3组的肿瘤体积为(1 514.5±251.5)mm3,大于OE-NC组(P=0.005)。 结论: 在GBM中,CMMT3呈高表达并且CMTM3高表达GBM患者的总生存率和无病生存率降低。CMTM3可以通过NF-κB信号通路来调控U251细胞的增殖和迁移能力。.
引用
- Jiang LS, Teng W, Qiu WJ, et al. [CMTM3 regulates proliferation and migration of glioblastoma U251 cells via the NF-κB signaling pathway]. Zhonghua Zhong Liu Za Zhi. 2025. PMID: 39939015. doi:10.3760/cma.j.cn112152-20240213-00072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。